{"id":"mupirocin","rwe":[{"pmid":"41900409","year":"2026","title":"In Vitro Activity of Mupirocin Against Methicillin-Resistant Staphylococcus aureus (MRSA) in Two Periods of Time (2016 and 2021-2022) in a Large University Hospital in Germany.","finding":"","journal":"Microorganisms","studyType":"Clinical Study"},{"pmid":"41892459","year":"2026","title":"Iron(III)-Tropolone Complex as a Topical Agent Against Drug-Resistant MRSA Skin Infections.","finding":"","journal":"Antibiotics (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41862082","year":"2026","title":"Mupirocin-based Nasal Decolonization to Prevent Staphylococcus aureus Surgical Site Infections: A Meta-Analysis of Randomized Control Trials.","finding":"","journal":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","studyType":"Clinical Study"},{"pmid":"41839109","year":"2026","title":"Impetigo: Rapid Evidence Review.","finding":"","journal":"American family physician","studyType":"Clinical Study"},{"pmid":"41834997","year":"2026","title":"Synergistic activity of mupirocin in combination with protocatechuic acid ethyl ester against mupirocin-resistant MRSA.","finding":"","journal":"Frontiers in cellular and infection microbiology","studyType":"Clinical Study"}],"_fda":{"id":"9c983738-f481-4e39-b812-69b45c7e9401","set_id":"0580458d-7178-4031-8ac7-0cda281ade8b","openfda":{"upc":["0346708624156"],"unii":["RG38I2P540"],"route":["TOPICAL"],"rxcui":["311877"],"spl_id":["9c983738-f481-4e39-b812-69b45c7e9401"],"brand_name":["MUPIROCIN"],"spl_set_id":["0580458d-7178-4031-8ac7-0cda281ade8b"],"package_ndc":["46708-624-15","46708-624-30"],"product_ndc":["46708-624"],"generic_name":["MUPIROCIN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["MUPIROCIN CALCIUM"],"manufacturer_name":["Alembic Pharmaceuticals Limited"],"application_number":["ANDA213053"],"is_original_packager":[true]},"version":"1","pregnancy":["8.1 Pregnancy Risk Summary There are insufficient human data to establish whether there is a drug-associated risk with mupirocin cream in pregnant women. Systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin cream [see Clinical Pharmacology ( 12.3 )] . No developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. The estimated background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies. Data Animal Data: Developmental toxicity studies have been performed with mupirocin administered subcutaneously to rats and rabbits at doses up to 160 mg per kg per day during organogenesis. This dose is 22 and 43 times, respectively, the human topical dose (approximately 60 mg mupirocin per day) based on calculations of dose divided by the entire body surface area. Maternal toxicity was observed (body weight loss/decreased body weight gain and reduced feeding) in both species with no evidence of developmental toxicity in rats. In rabbits, excessive maternal toxicity at the high dose precluded the evaluation of fetal outcomes. There was no developmental toxicity in rabbits at 40 mg per kg per day, 11 times the human topical dose based on calculations of dose divided by the entire body surface area. Mupirocin administered subcutaneously to rats in a prenatal and postnatal development study (dosed during late gestation through lactation) was associated with reduced offspring viability in the early postnatal period at a dose of 106.7 mg per kg, in the presence of injection site irritation and/or subcutaneous hemorrhaging. This dose is 14 times the human topical dose based on calculations of dose divided by the entire body surface area. The no-observed adverse effect level in this study was 44.2 mg per kg per day, which is 6 times the human topical dose."],"references":["15 REFERENCES Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-sixth Informational Supplement. CLSI document M100-S26. Clinical and Laboratory Standards Institute, 950 West Valley Rd., Suite 2500, Wayne, PA 19087, USA, 2016. Patel J, Gorwitz RJ, et al. Mupirocin Resistance. Clinical Infectious Diseases. 2009; 49(6): 935-41. Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard – Tenth Edition. CLSI document M07-A10. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard – Twelfth Edition. CLSI document M02-A12. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015. Finlay JE, Miller LA, Poupard JA. Interpretive criteria for testing susceptibility of staphylococci to mupirocin. Antimicrob Agents Chemother. 1997; 41(5):1137-1139."],"description":["11 DESCRIPTION Mupirocin cream USP, 2% contains the dihydrate crystalline calcium hemi-salt of the RNA synthetase inhibitor antibacterial, mupirocin. Chemically, it is (α E ,2 S ,3 R ,4 R ,5 S )-5-[(2 S ,3 S ,4 S ,5 S )-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-β-methyl-2 H -pyran-2-crotonic acid, ester with 9-hydroxynonanoic acid, calcium salt (2:1), dihydrate. The molecular formula of mupirocin calcium is (C 26 H 43 O 9 ) 2 Ca•2H 2 O, and the molecular weight is 1075.3. The molecular weight of mupirocin free acid is 500.6. The structural formula of mupirocin calcium is: Each gram of mupirocin cream USP, 2% contains 20 mg (2% w/w) of mupirocin equivalent to 21.5 mg (2.15% w/w) of mupirocin calcium, USP. The inactive ingredients are benzyl alcohol, glycerol monostearate, mineral oil, phenoxyethanol, polyoxyl 20 cetostearyl ether, purified water, and xanthan gum. Image"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Mupirocin cream USP, 2% is a white to off white cream that contains 20 mg (2% w/w) of mupirocin per gram in an oil-and water-based emulsion. Mupirocin cream USP, 2% is supplied in 15-gram and 30-gram tubes. NDC 46708-624-15 (15-gram tube) NDC 46708-624-30 (30-gram tube) Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Do not freeze."],"microbiology":["12.4 Microbiology Mupirocin is an RNA synthetase inhibitor antibacterial produced by fermentation using the organism Pseudomonas fluorescens . Mechanism of Action Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl-transfer RNA (tRNA) synthetase. Mupirocin is bactericidal at concentrations achieved by topical administration. Mupirocin is highly protein bound (greater than 97%) and the effect of wound secretions on the minimum inhibitory concentrations (MICs) of mupirocin has not been determined. Resistance When mupirocin resistance occurs, it results from the production of a modified isoleucyl-tRNA synthetase, or the acquisition of, by genetic transfer, a plasmid mediating a new isoleucyl-tRNA synthetase. High-level plasmid-mediated resistance (MIC ≥512 mcg/mL) has been reported in increasing numbers of isolates of S. aureus and with higher frequency in coagulase-negative staphylococci. Mupirocin resistance occurs with greater frequency in methicillin-resistant than methicillin-susceptible staphylococci. Cross Resistance Due to its mode of action, mupirocin does not demonstrate cross resistance with other classes of antimicrobial agents. Antimicrobial Activity Mupirocin has been shown to be active against susceptible isolates of S. aureus and S. pyogenes , both in vitro and in clinical trials [see Indications and Usage ( 1 )]. The following in vitro data are available, but their clinical significance is unknown. Mupirocin is active against most isolates of Staphylococcus epidermidis . Susceptibility Test Methods High-level mupirocin resistance (≥512 mcg/mL) may be determined using standard disk diffusion or broth microdilution tests. 1,2 Because of the occurrence of mupirocin resistance in methicillin-resistant S. aureus (MRSA), it is appropriate to test MRSA populations for mupirocin susceptibility prior to the use of mupirocin using a standardized method. 3,4,5"],"geriatric_use":["8.5 Geriatric Use In 2 adequate and well‑controlled trials, 30 subjects older than 65 years were treated with mupirocin cream. No overall difference in the efficacy or safety of mupirocin cream was observed in this patient population when compared with that observed in younger patients."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of mupirocin cream have been established in the age-groups 3 months to 16 years. Use of mupirocin cream in these age-groups is supported by evidence from adequate and well‑controlled trials of mupirocin cream in adults with additional data from 93 pediatric subjects studied as part of the pivotal trials in adults [see Clinical Studies ( 14 )] ."],"effective_time":"20250318","clinical_studies":["14 CLINICAL STUDIES The efficacy of topical mupirocin cream for the treatment of secondarily infected traumatic skin lesions (e.g., lacerations, sutured wounds, and abrasions not more than 10 cm in length or 100 cm 2 in total area) was compared with that of oral cephalexin in 2 randomized, double‑blind, double‑dummy clinical trials. Clinical efficacy rates at follow‑up in the per-protocol populations (adults and pediatric subjects included) were 96.1% for mupirocin cream (n = 231) and 93.1% for oral cephalexin (n = 219). Pathogen eradication rates at follow‑up in the per-protocol populations were 100% for both mupirocin cream and oral cephalexin. Pediatrics There were 93 pediatric subjects aged 2 weeks to 16 years enrolled per protocol in the secondarily infected skin lesion trials, although only 3 were younger than 2 years of age in the population treated with mupirocin cream. Subjects were randomized to either 10 days of topical mupirocin cream 3 times daily or 10 days of oral cephalexin (250 mg 4 times daily for subjects greater than 40 kg or 25 mg per kg per day oral suspension in 4 divided doses for subjects less than or equal to 40 kg). Clinical efficacy at follow‑up (7 to 12 days post-therapy) in the per-protocol populations was 97.7% (43 of 44) for mupirocin cream and 93.9% (46 of 49) for cephalexin."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption Systemic absorption of mupirocin through intact human skin is minimal. The systemic absorption of mupirocin was studied following application of mupirocin cream 3 times daily for 5 days to various skin lesions greater than 10 cm in length or 100 cm 2 in area in 16 adults (aged 29 to 60 years) and 10 children (aged 3 to 12 years). Some systemic absorption was observed as evidenced by the detection of the metabolite, monic acid, in urine. Data from this trial indicated more frequent occurrence of percutaneous absorption in children (90% of subjects) compared with adults (44% of subjects); however, the observed urinary concentrations in children (0.07 to 1.3 mcg per mL [1 pediatric subject had no detectable level]) are within the observed range (0.08 to 10.03 mcg per mL [9 adults had no detectable level]) in the adult population. In general, the degree of percutaneous absorption following multiple dosing appears to be minimal in adults and children. The effect of the concurrent application of mupirocin cream with other topical products has not been studied [see Dosage and Administration ( 2 )]. Elimination In a trial conducted in 7 healthy adult male subjects, the elimination half-life after intravenous administration of mupirocin was 20 to 40 minutes for mupirocin and 30 to 80 minutes for monic acid. Metabolism : Following intravenous or oral administration, mupirocin is rapidly metabolized. The principal metabolite, monic acid, demonstrates no antibacterial activity. Excretion : Monic acid is predominantly eliminated by renal excretion."],"adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail in other sections of the labeling: Severe Allergic Reactions [see Warnings and Precautions ( 5.1 )] Eye Irritation [see Warnings and Precautions ( 5.2 )] Local Irritation [see Warnings and Precautions ( 5.3 )] Clostridium difficile -Associated Diarrhea [see Warnings and Precautions ( 5.4 )] The most frequent adverse reactions (at least 1%) were headache, rash, and nausea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. In 2 randomized, double‑blind, double‑dummy trials, 339 subjects were treated with topical mupirocin cream plus oral placebo. Adverse reactions occurred in 28 (8.3%) subjects. The following adverse reactions were reported by at least 1% of subjects in connection with the use of mupirocin cream in clinical trials: headache (1.7%), rash (1.1%), and nausea (1.1%). Other adverse reactions which occurred in less than 1% of subjects were: abdominal pain, burning at application site, cellulitis, dermatitis, dizziness, pruritus, secondary wound infection, and ulcerative stomatitis. In a supportive trial in the treatment of secondarily infected eczema, 82 subjects were treated with mupirocin cream. The incidence of adverse reactions was as follows: nausea (4.9%), headache and burning at application site (3.6% each), pruritus (2.4%), and 1 report each of abdominal pain, bleeding secondary to eczema, pain secondary to eczema, hives, dry skin, and rash. 6.2 Postmarketing Experience In addition to adverse reactions reported from clinical trials, the following reactions have been identified during postmarketing use of mupirocin cream. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal relationship to mupirocin cream. Immune System Disorders Systemic allergic reactions, including anaphylaxis, urticaria, angioedema, and generalized rash [see Warnings and Precautions ( 5.1 )] ."],"contraindications":["4 CONTRAINDICATIONS Mupirocin cream is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin cream. Known hypersensitivity to mupirocin or any of the excipients of mupirocin cream. ( 4 )"],"mechanism_of_action":["12.1 Mechanism of Action Mupirocin is an RNA synthetase inhibitor antibacterial [see Microbiology ( 12.4 )]."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Mupirocin is an RNA synthetase inhibitor antibacterial [see Microbiology ( 12.4 )]. 12.3 Pharmacokinetics Absorption Systemic absorption of mupirocin through intact human skin is minimal. The systemic absorption of mupirocin was studied following application of mupirocin cream 3 times daily for 5 days to various skin lesions greater than 10 cm in length or 100 cm 2 in area in 16 adults (aged 29 to 60 years) and 10 children (aged 3 to 12 years). Some systemic absorption was observed as evidenced by the detection of the metabolite, monic acid, in urine. Data from this trial indicated more frequent occurrence of percutaneous absorption in children (90% of subjects) compared with adults (44% of subjects); however, the observed urinary concentrations in children (0.07 to 1.3 mcg per mL [1 pediatric subject had no detectable level]) are within the observed range (0.08 to 10.03 mcg per mL [9 adults had no detectable level]) in the adult population. In general, the degree of percutaneous absorption following multiple dosing appears to be minimal in adults and children. The effect of the concurrent application of mupirocin cream with other topical products has not been studied [see Dosage and Administration ( 2 )]. Elimination In a trial conducted in 7 healthy adult male subjects, the elimination half-life after intravenous administration of mupirocin was 20 to 40 minutes for mupirocin and 30 to 80 minutes for monic acid. Metabolism : Following intravenous or oral administration, mupirocin is rapidly metabolized. The principal metabolite, monic acid, demonstrates no antibacterial activity. Excretion : Monic acid is predominantly eliminated by renal excretion. 12.4 Microbiology Mupirocin is an RNA synthetase inhibitor antibacterial produced by fermentation using the organism Pseudomonas fluorescens . Mechanism of Action Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl-transfer RNA (tRNA) synthetase. Mupirocin is bactericidal at concentrations achieved by topical administration. Mupirocin is highly protein bound (greater than 97%) and the effect of wound secretions on the minimum inhibitory concentrations (MICs) of mupirocin has not been determined. Resistance When mupirocin resistance occurs, it results from the production of a modified isoleucyl-tRNA synthetase, or the acquisition of, by genetic transfer, a plasmid mediating a new isoleucyl-tRNA synthetase. High-level plasmid-mediated resistance (MIC ≥512 mcg/mL) has been reported in increasing numbers of isolates of S. aureus and with higher frequency in coagulase-negative staphylococci. Mupirocin resistance occurs with greater frequency in methicillin-resistant than methicillin-susceptible staphylococci. Cross Resistance Due to its mode of action, mupirocin does not demonstrate cross resistance with other classes of antimicrobial agents. Antimicrobial Activity Mupirocin has been shown to be active against susceptible isolates of S. aureus and S. pyogenes , both in vitro and in clinical trials [see Indications and Usage ( 1 )]. The following in vitro data are available, but their clinical significance is unknown. Mupirocin is active against most isolates of Staphylococcus epidermidis . Susceptibility Test Methods High-level mupirocin resistance (≥512 mcg/mL) may be determined using standard disk diffusion or broth microdilution tests. 1,2 Because of the occurrence of mupirocin resistance in methicillin-resistant S. aureus (MRSA), it is appropriate to test MRSA populations for mupirocin susceptibility prior to the use of mupirocin using a standardized method. 3,4,5"],"indications_and_usage":["1 INDICATIONS AND USAGE Mupirocin cream is indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm 2 in area) due to susceptible isolates of Staphylococcus aureus (S. aureus) and Streptococcus pyogenes (S. pyogenes) . Mupirocin cream is an RNA synthetase inhibitor antibacterial indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm 2 in area) due to susceptible isolates of Staphylococcus aureus and Streptococcus pyogenes . ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Severe Allergic Reactions: Anaphylaxis, urticaria, angioedema, and generalized rash have been reported in patients treated with formulations of mupirocin, including mupirocin cream. ( 5.1 ) Eye Irritation: Avoid contact with eyes. ( 5.2 ) Local Irritation: Discontinue in the event of sensitization or severe local irritation. ( 5.3 ) Clostridium difficile -Associated Diarrhea (CDAD): If diarrhea occurs, evaluate patients for CDAD. ( 5.4 ) Potential for Microbial Overgrowth: Prolonged use may result in overgrowth of nonsusceptible microorganisms, including fungi. ( 5.5 ) Risk Associated with Mucosal Use: Mupirocin cream is not formulated for use on mucosal surfaces. A separate formulation, BACTROBAN nasal ointment, is available for intranasal use. ( 5.6 ) 5.1 Severe Allergic Reactions Systemic allergic reactions, including anaphylaxis, urticaria, angioedema, and generalized rash, have been reported in patients treated with formulations of mupirocin, including mupirocin cream [see Adverse Reactions ( 6.2 )] . 5.2 Eye Irritation Avoid contact with the eyes. In case of accidental contact, rinse well with water. 5.3 Local Irritation In the event of a sensitization or severe local irritation from mupirocin cream, usage should be discontinued, and appropriate alternative therapy for the infection instituted. 5.4 Clostridium difficile -Associated Diarrhea Clostridium difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated. 5.5 Potential for Microbial Overgrowth As with other antibacterial products, prolonged use of mupirocin cream may result in overgrowth of nonsusceptible microorganisms, including fungi [see Dosage and Administration ( 2 )] . 5.6 Risk Associated with Mucosal Use Mupirocin cream is not formulated for use on mucosal surfaces. A separate formulation, BACTROBAN (mupirocin calcium) nasal ointment, is available for intranasal use."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long‑term studies in animals to evaluate carcinogenic potential of mupirocin calcium have not been conducted. Results of the following studies performed with mupirocin calcium or mupirocin sodium in vitro and in vivo did not indicate a potential for genotoxicity: rat primary hepatocyte unscheduled DNA synthesis, sediment analysis for DNA strand breaks, Salmonella reversion test (Ames), Escherichia coli mutation assay, metaphase analysis of human lymphocytes, mouse lymphoma assay, and bone marrow micronuclei assay in mice. In a fertility/reproductive performance study (with dosing through lactation), mupirocin administered subcutaneously to male and female rats at doses up to 100 mg per kg per day which is 14 times the human topical dose (approximately 60 mg mupirocin per day) based on calculations of dose divided by the entire body surface area, did not result in impaired fertility or impaired reproductive performance attributable to mupirocin."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). Advise the patient to administer mupirocin cream as follows: Use mupirocin cream only as directed by the healthcare provider. It is for external use only. Avoid contact of mupirocin cream with the eyes. If mupirocin cream gets in the eyes, rinse thoroughly with water. Do not use mupirocin cream in the nose. Wash your hands before and after applying mupirocin cream. Use a gauze pad or cotton swab to apply a small amount of mupirocin cream to the affected area. The treated area may be covered by gauze dressing if desired. Report to the healthcare provider any signs of local adverse reactions. mupirocin cream should be stopped and the healthcare provider contacted if irritation, severe itching, or rash occurs. Report to the healthcare provider or go to the nearest emergency room if severe allergic reactions, such as swelling of the lips, face, or tongue, or wheezing occur [see Warnings and Precautions ( 5.1 )] . If no improvement is seen in 3 to 5 days, contact the healthcare provider. Manufactured by: Alembic Pharmaceuticals Limited (Derma Division), Karakhadi, Vadodara 391450, India. Mfg. License No.: G/25/2216 PHARMACIST-DETACH HERE AND GIVE INSTRUCTIONS TO PATIENT -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- PATIENT INFORMATION Mupirocin (mue-PIR-oh-sin) cream, for topical use What is mupirocin cream? Mupirocin cream is a prescription medicine used on the skin (topical use) to treat certain skin infections caused by bacteria called Staphylococcus aureus and Streptococcus pyogenes . It is not known if mupirocin cream is safe and effective in children under 3 months of age. Who should not use mupirocin cream? Do not use mupirocin cream if: you are allergic to mupirocin or any of the ingredients in mupirocin cream. See the end of this Patient Information leaflet for a complete list of the ingredients in mupirocin cream What should I tell my healthcare provider before using mupirocin cream? Before using mupirocin cream, tell your healthcare provider about all of your medical conditions including if you: are pregnant or plan to become pregnant. It is not known if mupirocin cream will harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if mupirocin cream passes into your breast milk. You and your healthcare provider should decide if you can use mupirocin cream while breastfeeding. Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Do not mix mupirocin cream with other lotions, creams, or ointments. How should I use mupirocin cream? Mupirocin cream is for use on the skin (topical). Do not get mupirocin cream in your eyes, nose, mouth, or vagina (mucosal surfaces). Use mupirocin cream exactly as your healthcare provider tells you to use it. Apply a small amount of mupirocin cream, with a cotton swab or gauze pad, to the affected area 3 times each day. Apply mupirocin cream for 10 days. It is important that you take the full course of mupirocin cream not stop early because your symptoms may disappear before the infection is fully cleared. Wash your hands before and after applying mupirocin cream. After applying mupirocin cream, you may cover the treated area with a clean gauze pad, unless your healthcare provider has told you to leave it uncovered. Talk to your healthcare provider if your skin does not improve after 3 to 5 days of treatment with mupirocin cream. If you are breastfeeding and use mupirocin cream on your breast or nipple, wash the area well before breastfeeding your child. What are the possible side effects of mupirocin cream? Mupirocin cream may cause serious side effects, including: severe allergic reactions . Stop using mupirocin cream and call your healthcare provider or go to the nearest emergency room right away if you have any of the following signs or symptoms of a severe allergic reaction: ○ hives ○ trouble breathing or wheezing ○ swelling of your face, lips, mouth, or tongue ○ dizziness, fast heartbeat, or pounding in your chest ○ a rash over your whole body eye irritation . Do not get mupirocin cream in your eyes. If mupirocin cream gets in your eyes, rinse your eyes well with water. irritation in the area mupirocin cream is used . A rash may occur after using mupirocin cream and can be severe. Stop using mupirocin cream and call your healthcare provider if you develop an irritation, severe itching, or a rash while using mupirocin cream. a type of diarrhea called clostridium difficile -associated diarrhea (CDAD). CDAD may happen in people who use or have used medicine to treat bacterial infections. The severity of CDAD can range from mild diarrhea to severe diarrhea that may cause death (fatal colitis). Call your healthcare provider or go to the nearest emergency room right away if you have diarrhea while using or after you stop using mupirocin cream. The most common side effects of mupirocin cream include: headache rash nausea These are not all the possible side effects of mupirocin cream. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store mupirocin cream? Store mupirocin cream at room temperature between 68°F to 77°F (20°C to 25°C). Do not freeze mupirocin cream. Keep mupirocin cream and all medicines out of the reach of children. General information about the safe and effective use of mupirocin cream. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use mupirocin cream for a condition for which it was not prescribed. Do not give mupirocin cream to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about mupirocin cream that is written for health professionals. What are the ingredients in mupirocin cream? Active Ingredient: mupirocin calcium Inactive Ingredients: benzyl alcohol, glycerol monostearate, mineral oil, phenoxyethanol, polyoxyl 20 cetostearyl ether, purified water, and xanthan gum. Manufactured by: Alembic Pharmaceuticals Limited (Derma Division), Karakhadi, Vadodara 391450, India. Mfg. License No.: G/25/2216 For more information, call 1-866-210-9797 This Patient Information has been approved by the U.S. Food and Drug Administration Revised: 03/2025"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION For Topical Use Only. Apply a small amount of mupirocin cream, with a cotton swab or gauze pad, to the affected area 3 times daily for 10 days. Cover the treated area with gauze dressing if desired. Re-evaluate patients not showing a clinical response within 3 to 5 days. Mupirocin cream is not for intranasal, ophthalmic, or other mucosal use [see Warnings and Precautions ( 5.2 , 5.6 )]. Do not apply mupirocin cream concurrently with any other lotions, creams or ointments [see Clinical Pharmacology ( 12.3 )]. For Topical Use Only. ( 2 ) Apply a small amount of mupirocin cream, with a cotton swab or gauze pad, to the affected area 3 times daily for 10 days. ( 2 ) Re-evaluate patients not showing a clinical response within 3 to 5 days. ( 2 ) Not for intranasal, ophthalmic, or other mucosal use. ( 2 )"],"spl_product_data_elements":["MUPIROCIN MUPIROCIN MUPIROCIN CALCIUM MUPIROCIN BENZYL ALCOHOL GLYCERYL MONOSTEARATE MINERAL OIL PHENOXYETHANOL POLYOXYL 20 CETOSTEARYL ETHER XANTHAN GUM WATER"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Mupirocin cream USP, 2% is a white to off white cream that contains 20 mg (2% w/w) of mupirocin per gram in an oil-and water-based emulsion, supplied in 15-gram and 30-gram tubes. Cream: 20 mg (2% w/w) of mupirocin per gram in 15-gram and 30-gram tubes. ( 3 )"],"spl_patient_package_insert":[""],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are insufficient human data to establish whether there is a drug-associated risk with mupirocin cream in pregnant women. Systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin cream [see Clinical Pharmacology ( 12.3 )] . No developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. The estimated background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies. Data Animal Data: Developmental toxicity studies have been performed with mupirocin administered subcutaneously to rats and rabbits at doses up to 160 mg per kg per day during organogenesis. This dose is 22 and 43 times, respectively, the human topical dose (approximately 60 mg mupirocin per day) based on calculations of dose divided by the entire body surface area. Maternal toxicity was observed (body weight loss/decreased body weight gain and reduced feeding) in both species with no evidence of developmental toxicity in rats. In rabbits, excessive maternal toxicity at the high dose precluded the evaluation of fetal outcomes. There was no developmental toxicity in rabbits at 40 mg per kg per day, 11 times the human topical dose based on calculations of dose divided by the entire body surface area. Mupirocin administered subcutaneously to rats in a prenatal and postnatal development study (dosed during late gestation through lactation) was associated with reduced offspring viability in the early postnatal period at a dose of 106.7 mg per kg, in the presence of injection site irritation and/or subcutaneous hemorrhaging. This dose is 14 times the human topical dose based on calculations of dose divided by the entire body surface area. The no-observed adverse effect level in this study was 44.2 mg per kg per day, which is 6 times the human topical dose. 8.2 Lactation Risk Summary It is not known whether mupirocin is present in human milk, has effects on the breastfed child, or has effects on milk production. However, breastfeeding is not expected to result in exposure of the child to the drug due to the minimal systemic absorption of mupirocin in humans following topical administration of mupirocin cream [see Clinical Pharmacology ( 12.3 )] . The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for mupirocin cream and any potential adverse effects on the breastfed child from mupirocin cream or from the underlying maternal condition. Clinical Considerations To minimize oral exposure of the drug to children, a breast and/or nipple being treated with mupirocin cream should be thoroughly washed prior to breastfeeding. 8.4 Pediatric Use The safety and effectiveness of mupirocin cream have been established in the age-groups 3 months to 16 years. Use of mupirocin cream in these age-groups is supported by evidence from adequate and well‑controlled trials of mupirocin cream in adults with additional data from 93 pediatric subjects studied as part of the pivotal trials in adults [see Clinical Studies ( 14 )] . 8.5 Geriatric Use In 2 adequate and well‑controlled trials, 30 subjects older than 65 years were treated with mupirocin cream. No overall difference in the efficacy or safety of mupirocin cream was observed in this patient population when compared with that observed in younger patients."],"information_for_patients_table":["
PATIENT INFORMATION Mupirocin (mue-PIR-oh-sin) cream, for topical use
What is mupirocin cream? Mupirocin cream is a prescription medicine used on the skin (topical use) to treat certain skin infections caused by bacteria called Staphylococcus aureus and Streptococcus pyogenes . It is not known if mupirocin cream is safe and effective in children under 3 months of age.
Who should not use mupirocin cream? Do not use mupirocin cream if: you are allergic to mupirocin or any of the ingredients in mupirocin cream. See the end of this Patient Information leaflet for a complete list of the ingredients in mupirocin cream
What should I tell my healthcare provider before using mupirocin cream? Before using mupirocin cream, tell your healthcare provider about all of your medical conditions including if you: are pregnant or plan to become pregnant. It is not known if mupirocin cream will harm your unborn baby.are breastfeeding or plan to breastfeed. It is not known if mupirocin cream passes into your breast milk. You and your healthcare provider should decide if you can use mupirocin cream while breastfeeding. Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Do not mix mupirocin cream with other lotions, creams, or ointments.
How should I use mupirocin cream? Mupirocin cream is for use on the skin (topical). Do not get mupirocin cream in your eyes, nose, mouth, or vagina (mucosal surfaces).Use mupirocin cream exactly as your healthcare provider tells you to use it. Apply a small amount of mupirocin cream, with a cotton swab or gauze pad, to the affected area 3 times each day. Apply mupirocin cream for 10 days.It is important that you take the full course of mupirocin cream not stop early because your symptoms may disappear before the infection is fully cleared.Wash your hands before and after applying mupirocin cream.After applying mupirocin cream, you may cover the treated area with a clean gauze pad, unless your healthcare provider has told you to leave it uncovered.Talk to your healthcare provider if your skin does not improve after 3 to 5 days of treatment with mupirocin cream.If you are breastfeeding and use mupirocin cream on your breast or nipple, wash the area well before breastfeeding your child.
What are the possible side effects of mupirocin cream? Mupirocin cream may cause serious side effects, including: severe allergic reactions . Stop using mupirocin cream and call your healthcare provider or go to the nearest emergency room right away if you have any of the following signs or symptoms of a severe allergic reaction:
○ hives ○ trouble breathing or wheezing
○ swelling of your face, lips, mouth, or tongue ○ dizziness, fast heartbeat, or pounding in your chest
○ a rash over your whole body
eye irritation . Do not get mupirocin cream in your eyes. If mupirocin cream gets in your eyes, rinse your eyes well with water. irritation in the area mupirocin cream is used . A rash may occur after using mupirocin cream and can be severe. Stop using mupirocin cream and call your healthcare provider if you develop an irritation, severe itching, or a rash while using mupirocin cream. a type of diarrhea called clostridium difficile -associated diarrhea (CDAD). CDAD may happen in people who use or have used medicine to treat bacterial infections. The severity of CDAD can range from mild diarrhea to severe diarrhea that may cause death (fatal colitis). Call your healthcare provider or go to the nearest emergency room right away if you have diarrhea while using or after you stop using mupirocin cream.
The most common side effects of mupirocin cream include: headacherashnausea These are not all the possible side effects of mupirocin cream. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store mupirocin cream? Store mupirocin cream at room temperature between 68°F to 77°F (20°C to 25°C). Do not freeze mupirocin cream. Keep mupirocin cream and all medicines out of the reach of children.
General information about the safe and effective use of mupirocin cream. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use mupirocin cream for a condition for which it was not prescribed. Do not give mupirocin cream to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about mupirocin cream that is written for health professionals.
What are the ingredients in mupirocin cream? Active Ingredient: mupirocin calcium Inactive Ingredients: benzyl alcohol, glycerol monostearate, mineral oil, phenoxyethanol, polyoxyl 20 cetostearyl ether, purified water, and xanthan gum. Manufactured by: Alembic Pharmaceuticals Limited (Derma Division), Karakhadi, Vadodara 391450, India. Mfg. License No.: G/25/2216 For more information, call 1-866-210-9797
"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL 15 gram Tube label NDC 46708-624-15 15 grams Mupirocin C ream USP, 2% 15 gram Carton label NDC 46708-624-15 15 grams Mupirocin C ream USP, 2% 15 g tube 15 g carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long‑term studies in animals to evaluate carcinogenic potential of mupirocin calcium have not been conducted. Results of the following studies performed with mupirocin calcium or mupirocin sodium in vitro and in vivo did not indicate a potential for genotoxicity: rat primary hepatocyte unscheduled DNA synthesis, sediment analysis for DNA strand breaks, Salmonella reversion test (Ames), Escherichia coli mutation assay, metaphase analysis of human lymphocytes, mouse lymphoma assay, and bone marrow micronuclei assay in mice. In a fertility/reproductive performance study (with dosing through lactation), mupirocin administered subcutaneously to male and female rats at doses up to 100 mg per kg per day which is 14 times the human topical dose (approximately 60 mg mupirocin per day) based on calculations of dose divided by the entire body surface area, did not result in impaired fertility or impaired reproductive performance attributable to mupirocin."]},"tags":[{"label":"RNA Synthetase Inhibitor Antibacterial","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Isoleucine--tRNA ligase, cytoplasmic","category":"target"},{"label":"IARS","category":"gene"},{"label":"D06AX09","category":"atc"},{"label":"Topical","category":"route"},{"label":"Cream","category":"form"},{"label":"Ointment","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Impetigo","category":"indication"},{"label":"Methicillin-Resistant Staphylococcus Aureus Nasal Colonization","category":"indication"},{"label":"Staph Aureus Traumatic Skin Lesion Infection","category":"indication"},{"label":"Traumatic Skin Lesion Streptococcus Pyogenes Infection","category":"indication"},{"label":"Glaxosmithkline","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Protein Synthesis Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":1143.309,"date":"","count":362,"signal":"Macular degeneration","source":"DrugCentral FAERS","actionTaken":"Reported 362 times (LLR=1143)"},{"llr":235.111,"date":"","count":97,"signal":"Chronic sinusitis","source":"DrugCentral FAERS","actionTaken":"Reported 97 times (LLR=235)"},{"llr":186.606,"date":"","count":96,"signal":"Procedural pain","source":"DrugCentral FAERS","actionTaken":"Reported 96 times (LLR=187)"},{"llr":177.882,"date":"","count":90,"signal":"Paraesthesia oral","source":"DrugCentral FAERS","actionTaken":"Reported 90 times (LLR=178)"},{"llr":114.003,"date":"","count":38,"signal":"Vaginal flatulence","source":"DrugCentral FAERS","actionTaken":"Reported 38 times (LLR=114)"},{"llr":99.933,"date":"","count":591,"signal":"Drug ineffective","source":"DrugCentral FAERS","actionTaken":"Reported 591 times (LLR=100)"},{"llr":89.38,"date":"","count":125,"signal":"Dyspepsia","source":"DrugCentral FAERS","actionTaken":"Reported 125 times (LLR=89)"},{"llr":88.406,"date":"","count":15,"signal":"Nasal vestibulitis","source":"DrugCentral FAERS","actionTaken":"Reported 15 times (LLR=88)"},{"llr":85.229,"date":"","count":38,"signal":"Female genital tract fistula","source":"DrugCentral FAERS","actionTaken":"Reported 38 times (LLR=85)"},{"llr":83.892,"date":"","count":46,"signal":"Dermatitis atopic","source":"DrugCentral FAERS","actionTaken":"Reported 46 times (LLR=84)"},{"llr":83.634,"date":"","count":140,"signal":"Therapeutic product effect incomplete","source":"DrugCentral FAERS","actionTaken":"Reported 140 times (LLR=84)"},{"llr":81.578,"date":"","count":38,"signal":"Proctitis","source":"DrugCentral FAERS","actionTaken":"Reported 38 times (LLR=82)"},{"llr":81.372,"date":"","count":39,"signal":"Vaginal discharge","source":"DrugCentral FAERS","actionTaken":"Reported 39 times (LLR=81)"},{"llr":75.992,"date":"","count":40,"signal":"Radiculopathy","source":"DrugCentral FAERS","actionTaken":"Reported 40 times (LLR=76)"},{"llr":70.92,"date":"","count":229,"signal":"Weight decreased","source":"DrugCentral FAERS","actionTaken":"Reported 229 times (LLR=71)"}],"commonSideEffects":[{"effect":"burning, stinging, or pain","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"itching","drugRate":"1%","severity":"mild","_validated":true},{"effect":"anaphylaxis","drugRate":"reported","severity":"unknown"},{"effect":"urticaria","drugRate":"reported","severity":"unknown"},{"effect":"angioedema","drugRate":"reported","severity":"unknown"},{"effect":"generalized rash","drugRate":"reported","severity":"unknown"}],"contraindications":["Skin irritation"],"specialPopulations":{"Lactation":"It is not known whether mupirocin is present in human milk, has effects on the breastfed child, or has effects on milk production. However, breastfeeding is not expected to result in exposure of the child to the drug due to the minimal systemic absorption of mupirocin in humans following topical administration of mupirocin ointment.","Pregnancy":"There are insufficient human data to establish whether there is drug-associated risk with mupirocin ointment in pregnant women. Systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment. No developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area).","Geriatric use":"In well-controlled studies, 30 patients older than 65 years were treated with BACTROBAN CREAM. No overall difference in the efficacy or safety of BACTROBAN CREAM was observed in this patient population when compared to that observed in younger patients.","Paediatric use":"The safety and effectiveness of mupirocin ointment have been established in the age range of 2 months to 16 years. Use of mupirocin ointment in these age groups is supported by evidence from adequate and well-controlled trials of mupirocin ointment in impetigo in pediatric subjects studied as part of the pivotal clinical trials."}},"trials":[],"aliases":[],"company":"GSK","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$1.9702/GM","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$719","description":"MUPIROCIN 2% CREAM","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MUPIROCIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:46:15.006673+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Mupirocin","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:46:22.208994+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:46:20.726364+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MUPIROCIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:46:21.028165+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:46:13.886378+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:46:13.886409+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Isoleucyl-tRNA synthetase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:46:22.208947+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3989715/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:46:21.740404+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA213053","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:46:13.886413+00:00"}},"allNames":"bactroban","offLabel":[],"synonyms":["mupirocin","mupricin","pseudomonic acid","turixin","mupirocin calcium","bactroban","BRL 4910A"],"timeline":[{"date":"1987-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from GLAXOSMITHKLINE to Glaxosmithkline"},{"date":"1987-12-31","type":"positive","source":"DrugCentral","milestone":"FDA approval (Glaxosmithkline)"},{"date":"2002-12-04","type":"positive","source":"FDA Orange Book","milestone":"Centany approved — 2%"},{"date":"2011-06-08","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 5 manufacturers approved"}],"aiSummary":"Bactroban (mupirocin) is a small molecule RNA synthetase inhibitor antibacterial developed by GlaxoSmithKline, targeting Isoleucine--tRNA ligase, cytoplasmic. It was FDA approved in 1987 for various skin infections, including impetigo, methicillin-resistant Staphylococcus aureus nasal colonization, and traumatic skin lesion infections. Bactroban is now off-patent with multiple generic manufacturers. As an antibacterial, it works by inhibiting protein synthesis in bacteria, ultimately leading to cell death. It is used topically to treat skin infections.","approvals":[{"date":"1987-12-31","orphan":false,"company":"GLAXOSMITHKLINE","regulator":"FDA"}],"brandName":"Bactroban","ecosystem":[{"indication":"Impetigo","otherDrugs":[{"name":"cefuroxime","slug":"cefuroxime","company":"Covis Injectables"},{"name":"cefuroxime axetil","slug":"cefuroxime-axetil","company":"Glaxosmithkline"},{"name":"retapamulin","slug":"retapamulin","company":"Glaxo Grp Ltd"}],"globalPrevalence":null},{"indication":"Methicillin-Resistant Staphylococcus Aureus Nasal Colonization","otherDrugs":[],"globalPrevalence":null},{"indication":"Staph Aureus Traumatic Skin Lesion Infection","otherDrugs":[],"globalPrevalence":null},{"indication":"Traumatic Skin Lesion Streptococcus Pyogenes Infection","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Isoleucine--tRNA ligase, cytoplasmic","novelty":"Follow-on","targets":[{"gene":"IARS","source":"DrugCentral","target":"Isoleucine--tRNA ligase, cytoplasmic","protein":"Isoleucine--tRNA ligase, cytoplasmic"}],"moaClass":"RNA Synthetase Inhibitors","modality":"Small Molecule","drugClass":"RNA Synthetase Inhibitor Antibacterial","explanation":"Mupirocin is an antibacterial drug [see Clinical Pharmacology (12.4)].","oneSentence":"Bactroban works by inhibiting the production of essential proteins in bacteria, preventing them from reproducing and causing infection.","technicalDetail":"Bactroban specifically targets Isoleucine--tRNA ligase, a cytoplasmic enzyme essential for protein synthesis in bacteria. By inhibiting this enzyme, Bactroban prevents the incorporation of isoleucine into proteins, ultimately leading to the death of the bacterial cell.","_target_confidence":0.5},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Mupirocin","title":"Mupirocin","extract":"Mupirocin, sold under the brand name Bactroban among others, is a topical antibiotic useful against superficial skin infections such as impetigo or folliculitis. It may also be used to get rid of methicillin-resistant S. aureus (MRSA) when present in the nose without symptoms. Out of concerns of developing resistance, use for greater than ten days is not recommended. It is used as a cream or ointment applied to the skin."},"commercial":{"launchDate":"1987","_launchSource":"DrugCentral (FDA 1987-12-31, GLAXOSMITHKLINE)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1857","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MUPIROCIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MUPIROCIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Mupirocin","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T14:35:01.476887","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:46:24.913035+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"chloramphenicol","drugSlug":"chloramphenicol","fdaApproval":"1950-12-08","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"neomycin","drugSlug":"neomycin","fdaApproval":"1957-03-26","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"bacitracin","drugSlug":"bacitracin","fdaApproval":"1948-07-29","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"gentamicin","drugSlug":"gentamicin","fdaApproval":"1970-06-19","genericCount":36,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"virginiamycin","drugSlug":"virginiamycin","fdaApproval":"","relationship":"same-class"},{"drugName":"rifaximin","drugSlug":"rifaximin","fdaApproval":"2004-05-25","patentExpiry":"Sep 2, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"amikacin","drugSlug":"amikacin","fdaApproval":"1981-01-22","patentExpiry":"May 15, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"retapamulin","drugSlug":"retapamulin","fdaApproval":"2007-04-12","patentExpiry":"Feb 14, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ozenoxacin","drugSlug":"ozenoxacin","fdaApproval":"2017-12-11","patentExpiry":"Jan 29, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"rifamycin","drugSlug":"rifamycin","fdaApproval":"2018-11-16","patentStatus":"Unknown","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"mupirocin","indications":{"approved":[{"name":"Impetigo","source":"DrugCentral","snomedId":48277006,"regulator":"FDA","eligibility":"No specific patient eligibility criteria mentioned"},{"name":"Methicillin-Resistant Staphylococcus Aureus Nasal Colonization","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Staph Aureus Traumatic Skin Lesion Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Traumatic Skin Lesion Streptococcus Pyogenes Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[{"name":"Atopic dermatitis","source":"DrugCentral","drugName":"MUPIROCIN","evidenceCount":37,"evidenceLevel":"moderate"},{"name":"Ecthyma","source":"DrugCentral","drugName":"MUPIROCIN","evidenceCount":4,"evidenceLevel":"emerging"},{"name":"Eczema","source":"DrugCentral","drugName":"MUPIROCIN","evidenceCount":25,"evidenceLevel":"moderate"},{"name":"Epidermolysis bullosa","source":"DrugCentral","drugName":"MUPIROCIN","evidenceCount":15,"evidenceLevel":"moderate"},{"name":"Folliculitis","source":"DrugCentral","drugName":"MUPIROCIN","evidenceCount":23,"evidenceLevel":"moderate"},{"name":"Furunculosis","source":"DrugCentral","drugName":"MUPIROCIN","evidenceCount":22,"evidenceLevel":"moderate"},{"name":"Minor Bacterial Skin Infections","source":"DrugCentral","drugName":"MUPIROCIN","evidenceCount":9,"evidenceLevel":"emerging"}],"pipeline":[]},"currentOwner":"Glaxosmithkline","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"chloramphenicol","brandName":"chloramphenicol","genericName":"chloramphenicol","approvalYear":"1950","relationship":"same-class"},{"drugId":"neomycin","brandName":"neomycin","genericName":"neomycin","approvalYear":"1957","relationship":"same-class"},{"drugId":"bacitracin","brandName":"bacitracin","genericName":"bacitracin","approvalYear":"1948","relationship":"same-class"},{"drugId":"gentamicin","brandName":"gentamicin","genericName":"gentamicin","approvalYear":"1970","relationship":"same-class"},{"drugId":"virginiamycin","brandName":"virginiamycin","genericName":"virginiamycin","approvalYear":"","relationship":"same-class"},{"drugId":"rifaximin","brandName":"rifaximin","genericName":"rifaximin","approvalYear":"2004","relationship":"same-class"},{"drugId":"amikacin","brandName":"amikacin","genericName":"amikacin","approvalYear":"1981","relationship":"same-class"},{"drugId":"retapamulin","brandName":"retapamulin","genericName":"retapamulin","approvalYear":"2007","relationship":"same-class"},{"drugId":"ozenoxacin","brandName":"ozenoxacin","genericName":"ozenoxacin","approvalYear":"2017","relationship":"same-class"},{"drugId":"rifamycin","brandName":"rifamycin","genericName":"rifamycin","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06397781","phase":"PHASE4","title":"Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients","status":"NOT_YET_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2031-01-01","conditions":["Atopic Dermatitis"],"enrollment":100,"completionDate":"2039-12"},{"nctId":"NCT02572791","phase":"PHASE4","title":"Staph Household Intervention for Eradication (SHINE)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2015-10","conditions":["Skin and Subcutaneous Tissue Bacterial Infections","Staphylococcus Aureus","MRSA - Methicillin Resistant Staphylococcus Aureus Infection"],"enrollment":835,"completionDate":"2024-12"},{"nctId":"NCT03489629","phase":"PHASE2","title":"STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2018-04-03","conditions":["Cystic Fibrosis"],"enrollment":37,"completionDate":"2026-01-31"},{"nctId":"NCT06712433","phase":"PHASE2","title":"Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO)","status":"NOT_YET_RECRUITING","sponsor":"Adam Olson","startDate":"2026-09-30","conditions":["Sarcoma,Soft Tissue"],"enrollment":31,"completionDate":"2028-09-30"},{"nctId":"NCT06378359","phase":"","title":"Effectiveness of Screening and Decolonization of S. Aureus to Prevent S. Aureus Surgical Site Infections in Surgery Outpatients","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2024-01-29","conditions":["Staphylococcus Aureus Colonization","Surgical Site Infections","Healthcare Associated Infections"],"enrollment":250,"completionDate":"2026-12-31"},{"nctId":"NCT06210594","phase":"PHASE4","title":"Staph Intervention for Effective Local Defense","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2024-04-01","conditions":["Staphylococcus Aureus Infection"],"enrollment":78,"completionDate":"2025-11-14"},{"nctId":"NCT06541145","phase":"NA","title":"Bacterial Decolonization Within Dyads","status":"RECRUITING","sponsor":"Duke University","startDate":"2024-08-21","conditions":["Bacterial Colonization"],"enrollment":20,"completionDate":"2026-06"},{"nctId":"NCT01209234","phase":"NA","title":"Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2011-01","conditions":["Methicillin-resistant Staphylococcus Aureus"],"enrollment":2140,"completionDate":"2019-01"},{"nctId":"NCT04104178","phase":"PHASE3","title":"Optimal Treatment of MRSA Throat Carriers","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"2020-05-20","conditions":["MRSA","MRSA Colonization"],"enrollment":53,"completionDate":"2025-09-18"},{"nctId":"NCT06805994","phase":"PHASE1","title":"Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-08-27","conditions":["Staphylococcal Aureus Infection","Microbial Colonization","Pediatric Infection","S. Aureus Colonization","Microbial Transplant"],"enrollment":175,"completionDate":"2028-01-01"},{"nctId":"NCT07142408","phase":"PHASE3","title":"The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal","status":"RECRUITING","sponsor":"The Cooper Health System","startDate":"2023-03-13","conditions":["Surgical Wound Infection"],"enrollment":848,"completionDate":"2030-12"},{"nctId":"NCT07064161","phase":"NA","title":"Efficacy of Hydrocolloid Dressing vs. Topical Antibiotic on Wound Healing of Post-Punch Biopsy Wounds","status":"COMPLETED","sponsor":"University of Santo Tomas Hospital, Philippines","startDate":"2024-01-29","conditions":["Biopsy Wound"],"enrollment":60,"completionDate":"2024-10-07"},{"nctId":"NCT03935828","phase":"PHASE2","title":"Effect of Topical Sinonasal Antibiotics","status":"WITHDRAWN","sponsor":"United States Naval Medical Center, San Diego","startDate":"2019-06","conditions":["Chronic Rhinosinusitis (Diagnosis)","Antibiotic Side Effect"],"enrollment":0,"completionDate":"2021-06"},{"nctId":"NCT05586776","phase":"PHASE4","title":"Decolonization to Reduce After-Surgery Events of Surgical Site Infection","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2023-01-17","conditions":["Surgical Site Infection"],"enrollment":2700,"completionDate":"2028-12"},{"nctId":"NCT06368856","phase":"PHASE1","title":"Pharmacology of Mupirocin in Nasal Application in Healthy Volunteers: Monocentric Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2024-02-29","conditions":["Healthy","Staphylococcus Aureus Infection"],"enrollment":40,"completionDate":"2025-12"},{"nctId":"NCT07003750","phase":"NA","title":"Surgical Wound Infection Prevention Bundle in Patients Undergoing Coronary Bypass Graft Surgery","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2025-07-01","conditions":["Infection Due to Coronary Artery Bypass Graft (Diagnosis)"],"enrollment":200,"completionDate":"2026-06"},{"nctId":"NCT06633588","phase":"PHASE4","title":"Decolonization Efficacy of Polyhexanide vs. Mupirocin","status":"RECRUITING","sponsor":"Swiss Paraplegic Research, Nottwil","startDate":"2025-05-01","conditions":["Staphylococcus Aureus","Colonization, Asymptomatic"],"enrollment":24,"completionDate":"2027-04-30"},{"nctId":"NCT06968754","phase":"NA","title":"The Impact of Pharmaceutical Care on the Infection Control Measures Among Hemodialytic Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sulaimani","startDate":"2024-11-01","conditions":["Infection","Hemodialysis Patients"],"enrollment":90,"completionDate":"2025-05-15"},{"nctId":"NCT03140423","phase":"PHASE4","title":"Mupirocin-Iodophor ICU Decolonization Swap Out Trial","status":"COMPLETED","sponsor":"Harvard Pilgrim Health Care","startDate":"2017-05-01","conditions":["Staphylococcus Aureus"],"enrollment":353323,"completionDate":"2023-11-06"},{"nctId":"NCT00532324","phase":"NA","title":"A Prospective Cohort Pilot Study of the Clinical and Molecular Epidemiology of Staphylococcus Aureus in Pregnant Women at the Time of Group B Streptococcal Screening in a Large Urban Medical Center in Chicago, IL USA","status":"COMPLETED","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2008-02","conditions":["Staphylococcus Aureus"],"enrollment":107,"completionDate":"2013-10"},{"nctId":"NCT00626795","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2008-02","conditions":["Impetigo","Secondarily Infected Traumatic Lesions"],"enrollment":773,"completionDate":"2009-06"},{"nctId":"NCT00560599","phase":"PHASE3","title":"A Randomized Clinical Trial to Prevent Recurrent CA-MRSA Infection","status":"COMPLETED","sponsor":"loren g miller","startDate":"2007-04","conditions":["Methicillin Resistant Staphylococcus Aureus Skin Infections"],"enrollment":350,"completionDate":"2012-12"},{"nctId":"NCT02945722","phase":"PHASE4","title":"Study of the Impact of a Targeted Decolonization of S. Aureus Persistent Carriers","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2018-02-23","conditions":["Hemodialysis Patients"],"enrollment":434,"completionDate":"2024-10-26"},{"nctId":"NCT01313182","phase":"PHASE4","title":"Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin","status":"COMPLETED","sponsor":"Solventum US LLC","startDate":"2011-03","conditions":["Surgical Site Infection"],"enrollment":1874,"completionDate":"2012-09"},{"nctId":"NCT02127658","phase":"PHASE4","title":"MRSA Eradication and Decolonization in Children","status":"TERMINATED","sponsor":"Indiana University","startDate":"2016-02-18","conditions":["MRSA"],"enrollment":14,"completionDate":"2020-07-01"},{"nctId":"NCT04438174","phase":"PHASE1,PHASE2","title":"Processed Amniotic Fluid (pAF) for the Treatment of Chronic Wounds","status":"TERMINATED","sponsor":"University of Utah","startDate":"2022-08","conditions":["Wounds and Injuries"],"enrollment":1,"completionDate":"2023-03"},{"nctId":"NCT06291181","phase":"NA","title":"Studying the Distribution of Accessory Gene Regulator (Agr) Quorum Sensing System and the Prevalence of Linezolid and Mupirocin Resistance in Biofilm Producer/Non Producer Staphylococcus Aureus in Sohag University Hospitals","status":"COMPLETED","sponsor":"Sohag University","startDate":"2023-01-01","conditions":["Staphylococcus Aureus"],"enrollment":265,"completionDate":"2023-06-30"},{"nctId":"NCT05893810","phase":"PHASE3","title":"Bacterial Decolonization to Prevent Radiation-induced Oral Mucositis","status":"UNKNOWN","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2023-07-01","conditions":["Nasopharyngeal Carcinoma","Radiation-induced Oral Mucositis","Bacterial Colonization","Quality of Life"],"enrollment":176,"completionDate":"2024-12-31"},{"nctId":"NCT05505214","phase":"PHASE2","title":"Topical Steroids & Bacterial Decolonization for Radiation Dermatitis","status":"WITHDRAWN","sponsor":"Montefiore Medical Center","startDate":"2023-09-01","conditions":["Radiation Dermatitis"],"enrollment":0,"completionDate":"2025-09-01"},{"nctId":"NCT03677063","phase":"NA","title":"Usefulness of Sterile Adhesive Dressing at the Exit-site of Peritoneal Dialysis Catheter","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"2019-01-01","conditions":["Peritoneal Dialysis"],"enrollment":30,"completionDate":"2023-08-01"},{"nctId":"NCT03883828","phase":"PHASE2,PHASE3","title":"Bacterial Decolonization to Prevent Radiation Dermatitis","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2019-06-03","conditions":["Radiation Dermatitis"],"enrollment":80,"completionDate":"2021-12-02"},{"nctId":"NCT06046937","phase":"EARLY_PHASE1","title":"Monolaurin Ointment Versus Mupirocin Ointment","status":"COMPLETED","sponsor":"Victoriano Luna Medical Center","startDate":"2023-06-01","conditions":["Bacterial Infections"],"enrollment":40,"completionDate":"2023-07-15"},{"nctId":"NCT05874219","phase":"PHASE2,PHASE3","title":"Mupirocin 2% Ointment Vs Spray Antibiotics on Temporary Hemodialysis Catheter","status":"COMPLETED","sponsor":"Future University in Egypt","startDate":"2023-04-10","conditions":["Hemodialysis Complication","Hemodialysis Catheter Infection"],"enrollment":150,"completionDate":"2023-05-25"},{"nctId":"NCT04047914","phase":"NA","title":"Antimicrobial Photodynamic Therapy in the Nasal Decolonization of Maintenance Hemodialysis Patients","status":"COMPLETED","sponsor":"University of Nove de Julho","startDate":"2019-11-01","conditions":["Photochemotherapy","Renal Insufficiency, Chronic"],"enrollment":34,"completionDate":"2021-07-12"},{"nctId":"NCT05839158","phase":"NA","title":"Evaluation of the Effect of HFMT in Promoting Donor-site Wound Healing","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2022-03-01","conditions":["Wound Heal"],"enrollment":100,"completionDate":"2022-12-31"},{"nctId":"NCT04218799","phase":"PHASE4","title":"Human Microbiome and Healthcare Associated Infections - Nursing Home Dwelling Older Veterans","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2014-08-12","conditions":["Human Microbiome"],"enrollment":19,"completionDate":"2015-09-22"},{"nctId":"NCT00631566","phase":"NA","title":"Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons","status":"COMPLETED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2007-05","conditions":["HIV Infections","Staphylococcal Infections"],"enrollment":550,"completionDate":"2017-10"},{"nctId":"NCT04155203","phase":"PHASE3","title":"To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2019-10-15","conditions":["Secondarily Infected Traumatic Skin Lesions"],"enrollment":657,"completionDate":"2021-06-01"},{"nctId":"NCT04285697","phase":"NA","title":"Infection Prevention Bundle in Brain Tumor Surgery","status":"SUSPENDED","sponsor":"Istanbul University - Cerrahpasa","startDate":"2020-02-20","conditions":["Surgical Site Infection","Brain Tumor"],"enrollment":300,"completionDate":"2022-12-03"},{"nctId":"NCT03173053","phase":"NA","title":"S. Aureus Decolonization in HPN Patients.","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2018-02-08","conditions":["Staphylococcus Aureus","Motility Disorder"],"enrollment":63,"completionDate":"2021-10-14"},{"nctId":"NCT03673956","phase":"PHASE1,PHASE2","title":"Topical Antibiotics in Chronic Rhinosinusitis","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-09-26","conditions":["Chronic Rhinosinusitis (Diagnosis)"],"enrollment":19,"completionDate":"2021-02-01"},{"nctId":"NCT05251584","phase":"NA","title":"Effects of Topical Gentamicin on the Prevention of Peritoneal Dialysis Related Infection","status":"UNKNOWN","sponsor":"Phramongkutklao College of Medicine and Hospital","startDate":"2021-12-01","conditions":["Peritoneal Dialysis-related Infection"],"enrollment":60,"completionDate":"2023-05-31"},{"nctId":"NCT03685487","phase":"","title":"Decolonization of Patients Carrying S. Aureus Before Cardiac Surgery: Study of the Risk Factors Associated With Failure","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2019-02-12","conditions":["Staphylococcus Aureus"],"enrollment":215,"completionDate":"2020-03-10"},{"nctId":"NCT02223520","phase":"NA","title":"Treating Parents to Reduce NICU Transmission of Staphylococcus Aureus Trial","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2014-11","conditions":["Staph Aureus Colonization","Staph Aureus Infection"],"enrollment":307,"completionDate":"2019-10-31"},{"nctId":"NCT04951349","phase":"PHASE2","title":"Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.","status":"COMPLETED","sponsor":"Turn Therapeutics","startDate":"2021-01-21","conditions":["Covid19"],"enrollment":85,"completionDate":"2021-05-30"},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":["Osteomyelitis"],"enrollment":11,"completionDate":"2018-11-07"},{"nctId":"NCT04287777","phase":"PHASE3","title":"Safety and Efficacy of Mupirocin Gel in Children With Impetigo","status":"COMPLETED","sponsor":"Reig Jofre Group","startDate":"2014-02","conditions":["Impetigo"],"enrollment":467,"completionDate":"2016-11"},{"nctId":"NCT02216227","phase":"NA","title":"Checklist to Prevent MRSA Surgical Site Infections","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2014-04-01","conditions":["Surgical Site Infection"],"enrollment":1794,"completionDate":"2021-02-28"},{"nctId":"NCT02967432","phase":"PHASE2","title":"Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU","status":"COMPLETED","sponsor":"Crouse Hospital","startDate":"2016-10","conditions":["Staphylococcus"],"enrollment":216,"completionDate":"2019-12"},{"nctId":"NCT03962907","phase":"PHASE4","title":"Preoperative Decolonization and Surgical Site Infections in Orthopaedic Surgery - 2 Year Outcome in Prosthetic Surgery","status":"COMPLETED","sponsor":"Lindenhofgruppe AG","startDate":"2019-01-01","conditions":["Staphylococcus Aureus","Orthopaedic Surgery","Surgical Site Infection","Prevention"],"enrollment":1318,"completionDate":"2020-06-30"},{"nctId":"NCT04222699","phase":"PHASE4","title":"Cultures Before and After Decolonization in Community Dwelling Adults With Current S. Aureus Colonization","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2012-09-18","conditions":["Human Microbiome"],"enrollment":58,"completionDate":"2014-11-18"},{"nctId":"NCT01138462","phase":"NA","title":"Control of MRSA in Nursing Homes: Decolonization vs Standard Precautions","status":"COMPLETED","sponsor":"University of Lausanne Hospitals","startDate":"2010-06","conditions":["Methicillin-Resistant Staphylococcus Aureus"],"enrollment":157,"completionDate":"2011-12"},{"nctId":"NCT03304873","phase":"PHASE3","title":"Retapamulin as a Decolonizing Agent for MRSA","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2017-12-01","conditions":["MRSA"],"enrollment":47,"completionDate":"2019-03-18"},{"nctId":"NCT01438515","phase":"NA","title":"Randomized Controlled Trial of Standard Versus Systemic Decolonization Therapy for the Eradication of Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization","status":"COMPLETED","sponsor":"Horizon Health Network","startDate":"2008-08","conditions":["Methicillin-resistant Staphylococcus Aureus"],"enrollment":100,"completionDate":"2019-12-31"},{"nctId":"NCT02182115","phase":"PHASE4","title":"S. Aureus Screening and Decolonization","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2014-07","conditions":["Wound Infection Due to Staphylococcus Aureus","MRSA Infection of Postoperative Wound"],"enrollment":110,"completionDate":"2016-08"},{"nctId":"NCT01302210","phase":"","title":"Detection, Education, Research and Decolonization Without Isolation in Long-term Care Facilities","status":"COMPLETED","sponsor":"Endeavor Health","startDate":"2010-10","conditions":["Methicillin Resistant Staphylococcus Aureus"],"enrollment":22302,"completionDate":"2014-11"},{"nctId":"NCT02547103","phase":"PHASE4","title":"Chlorhexidine Gluconate Versus Mupirocin Ointment in the Prevention of Peritoneal Dialysis-Related Infection","status":"UNKNOWN","sponsor":"Chiang Mai University","startDate":"2016-06-01","conditions":["End Stage Renal Disease","Peritoneal Dialysis"],"enrollment":354,"completionDate":"2021-08"},{"nctId":"NCT02063867","phase":"NA","title":"Active Bathing to Eliminate Infection (ABATE Infection) Trial","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2014-04","conditions":["Healthcare Associated Infections","Methicillin Resistant Staphylococcus Aureus","Multi Drug Resistant Organisms"],"enrollment":53,"completionDate":"2019-02"},{"nctId":"NCT00966446","phase":"NA","title":"Epidemiology and Prevention of Methicillin Resistant Staphylococcus Aureus (MRSA) Transmission in the Community","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2009-09","conditions":["MRSA - Methicillin Resistant Staphylococcus Aureus Infection"],"enrollment":223,"completionDate":"2014-12"},{"nctId":"NCT01876550","phase":"PHASE1","title":"A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2013-02","conditions":["Secondarily Infected Traumatic Skin Lesions"],"enrollment":1902,"completionDate":"2019-05-06"},{"nctId":"NCT01594827","phase":"PHASE2","title":"Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2012-10","conditions":["Cystic Fibrosis"],"enrollment":29,"completionDate":"2017-12-30"},{"nctId":"NCT01814371","phase":"NA","title":"Individualized vs. Household MRSA Decolonization","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2013-04","conditions":["Staphylococcal Skin Infection","Abscess","Furunculosis","Staphylococcus Aureus","MRSA Infection"],"enrollment":474,"completionDate":"2017-11-28"},{"nctId":"NCT02619773","phase":"NA","title":"Effect of Mupirocin Dressings Versus Island Dressings on Surgical Site Infections in Elective Colorectal Surgery","status":"COMPLETED","sponsor":"Gundersen Lutheran Medical Foundation","startDate":"2015-11","conditions":["Surgical Site Infections"],"enrollment":150,"completionDate":"2018-12"},{"nctId":"NCT02045329","phase":"","title":"Impact of Mupirocin Decolonization on the Nasal Microbiome","status":"TERMINATED","sponsor":"VA Eastern Colorado Health Care System","startDate":"2013-10","conditions":["Nasal Colonization With Staph Aureus"],"enrollment":1,"completionDate":"2015-06-05"},{"nctId":"NCT01461668","phase":"PHASE4","title":"Retapamulin for Reducing MRSA Nasal Carriage","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2012-07","conditions":["Methicillin-Resistant Staphylococcus Aureus"],"enrollment":53,"completionDate":"2017-12"},{"nctId":"NCT03303677","phase":"PHASE3","title":"Comparison of Topical Therapies in Post op Endoscopic Sinus Surgery Patients","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2018-04-01","conditions":["Chronic Rhinosinusitis (Diagnosis)"],"enrollment":0,"completionDate":"2019-11-01"},{"nctId":"NCT02029872","phase":"PHASE4","title":"Stop Community MRSA Colonization Among Patients","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2014-01","conditions":["MRSA"],"enrollment":77,"completionDate":"2017-03"},{"nctId":"NCT02560155","phase":"NA","title":"Preoperative Decolonization and Surgical Site Infections - a Prospective Randomized Trial","status":"COMPLETED","sponsor":"Lindenhofgruppe AG","startDate":"2015-11","conditions":["Orthopedic Disorders","Surgical Site Infection"],"enrollment":1300,"completionDate":"2018-02"},{"nctId":"NCT01269541","phase":"NA","title":"MESS-study MRSA Eradication Study Skåne","status":"COMPLETED","sponsor":"Region Skane","startDate":"2011-03-01","conditions":["Throatcarriers of MRSA"],"enrollment":69,"completionDate":"2015-05-01"},{"nctId":"NCT02566928","phase":"PHASE4","title":"Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence","status":"UNKNOWN","sponsor":"Clinical Directors Network","startDate":"2015-10","conditions":["Methicillin-Resistant Staphylococcus Aureus","Recurrence","Staphylococcal Skin Infections","Antibiotic Resistance"],"enrollment":278,"completionDate":"2018-12-31"},{"nctId":"NCT01827358","phase":"PHASE2","title":"Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-04-30","conditions":["Staphylococcal Infection"],"enrollment":155,"completionDate":"2016-06-21"},{"nctId":"NCT03081962","phase":"PHASE3","title":"Effect of a Combination of Bundles on Surgical-site Infection After Elective Colorectal Surgery","status":"UNKNOWN","sponsor":"Hospital General Universitario Elche","startDate":"2017-02-15","conditions":["Surgical Site Infection"],"enrollment":102,"completionDate":"2017-08"},{"nctId":"NCT02218307","phase":"PHASE4","title":"The Use of Antibiotic Sinonasal Rinse After Sinus Surgery","status":"COMPLETED","sponsor":"University of Miami","startDate":"2011-11","conditions":["Chronic Rhinosinusitis"],"enrollment":68,"completionDate":"2015-06"},{"nctId":"NCT01349192","phase":"PHASE2","title":"Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2011-04","conditions":["Cystic Fibrosis","Methicillin-resistant Staphylococcus Aureus"],"enrollment":47,"completionDate":"2015-05"},{"nctId":"NCT00980980","phase":"NA","title":"Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs)","status":"COMPLETED","sponsor":"Harvard Pilgrim Health Care","startDate":"2009-09","conditions":["Methicillin-resistant Staphylococcus Aureus"],"enrollment":74256,"completionDate":"2011-09"},{"nctId":"NCT01537783","phase":"PHASE4","title":"Evaluation of a Staphylococcus Eradication Protocol for Patients Who Present to the ED With Cutaneous Abscess","status":"COMPLETED","sponsor":"Tufts Medical Center","startDate":"2011-09","conditions":["Cutaneous Abscess"],"enrollment":50,"completionDate":"2013-09"},{"nctId":"NCT00713674","phase":"NA","title":"Comparison of Decolonization of Methicillin-resistant Staphylococcus Aureus (MRSA) Using Theraworx","status":"WITHDRAWN","sponsor":"Mercy Research","startDate":"2008-03","conditions":["Methicillin-Resistant Staphylococcus Aureus"],"enrollment":0,"completionDate":"2009-02"},{"nctId":"NCT02963129","phase":"PHASE3","title":"Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT","status":"UNKNOWN","sponsor":"Hospital Italiano de Buenos Aires","startDate":"2017-06","conditions":["Hereditary Hemorrhagic Telangiectasia","Epistaxis"],"enrollment":40,"completionDate":"2017-12"},{"nctId":"NCT02284555","phase":"PHASE4","title":"Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)","status":"COMPLETED","sponsor":"Destiny Pharma Plc","startDate":"2014-08","conditions":["Staphylococcal Infection"],"enrollment":12,"completionDate":"2014-11"},{"nctId":"NCT00513799","phase":"NA","title":"The Natural History of Community-Associated MRSA Infections and Decolonization Strategies","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2007-03","conditions":["Abscesses","Furunculosis","Staphylococcus Aureus","Staphylococcal Skin Infections"],"enrollment":300,"completionDate":"2010-12"},{"nctId":"NCT01229553","phase":"NA","title":"Effect of Topical and Systemic Decolonization of Staphylococcus Aureus (SA) in Pediatric Cystic Fibrosis (CF) Patients","status":"WITHDRAWN","sponsor":"State University of New York - Upstate Medical University","startDate":"2011-01","conditions":["Cystic Fibrosis"],"enrollment":0,"completionDate":"2011-01"},{"nctId":"NCT00400595","phase":"PHASE4","title":"Use of Ointments in Prevention of Catheter Related Infections in PD","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2006-02","conditions":["End Stage Renal Disease"],"enrollment":200,"completionDate":"2010-06"},{"nctId":"NCT01820455","phase":"NA","title":"MRSA in a Trauma Population: Does Decolonization Prevent Infection?","status":"COMPLETED","sponsor":"University of Tennessee","startDate":"2012-01","conditions":["MRSA Colonization"],"enrollment":55,"completionDate":"2014-03"},{"nctId":"NCT00179959","phase":"PHASE4","title":"The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2005-09","conditions":["Atopic Dermatitis"],"enrollment":31,"completionDate":"2011-03"},{"nctId":"NCT00801879","phase":"PHASE4","title":"Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection","status":"COMPLETED","sponsor":"Columbia University","startDate":"2003-09","conditions":["Staphylococcus Aureus","HIV Infections"],"enrollment":100,"completionDate":"2006-04"},{"nctId":"NCT02267122","phase":"PHASE3","title":"Total Occlusive Ionic Silver-containing Dressing vs Mupirocin Ointment Application vs Conventional Dressing in Elective Colorectal Surgery: Effect on Incisional Surgical Site Infection","status":"COMPLETED","sponsor":"Hospital General Universitario Elche","startDate":"2012-01","conditions":["Incisional Surgical Site Infections"],"enrollment":147,"completionDate":"2014-01"},{"nctId":"NCT00108160","phase":"PHASE4","title":"Preventing Staphylococcal (Staph) Infection","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2005-04","conditions":["Staphylococcal Infections"],"enrollment":146,"completionDate":"2012-08"},{"nctId":"NCT01762982","phase":"NA","title":"Patch Test of Benzalkonium Chloride Disinfectant Spray","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-02","conditions":["Wound Healing"],"enrollment":36,"completionDate":"2012-02"},{"nctId":"NCT01408056","phase":"PHASE2","title":"Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)","status":"WITHDRAWN","sponsor":"Children's Hospital of Philadelphia","startDate":"2011-02","conditions":["Infantile Hemangiomas"],"enrollment":0,"completionDate":"2014-01"},{"nctId":"NCT01943136","phase":"PHASE1","title":"The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial","status":"UNKNOWN","sponsor":"Philippine Dermatological Society","startDate":"2013-08","conditions":["Impetigo"],"enrollment":128,"completionDate":""},{"nctId":"NCT01949935","phase":"PHASE3","title":"Efficacy Study of Mupirocin on Infection After Coronary Artery Bypass Grafting","status":"COMPLETED","sponsor":"Horizon Health Network","startDate":"2009-03","conditions":["Surgical Site Infections"],"enrollment":974,"completionDate":"2013-05"},{"nctId":"NCT00406913","phase":"NA","title":"Prophylaxis Prior to Cataract Surgery Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2005-10","conditions":["Endophthalmitis","Cataract Surgery","Prophylaxis"],"enrollment":37,"completionDate":"2006-11"},{"nctId":"NCT01918813","phase":"NA","title":"Risk of Methicillin-resistant S.Aureus (MRSA) Infections in MRSA Carrier Under Introduction of Rapid MRSA Screening","status":"COMPLETED","sponsor":"Chikara Tashiro","startDate":"2009-11","conditions":["Inflammatory Bowel Disease","Hepatobiliary Disease","Pancreas Disease"],"enrollment":662,"completionDate":"2012-02"},{"nctId":"NCT01400308","phase":"PHASE4","title":"Effectiveness of Two Protocols for Corporal Decolonization in Patients Colonized by Methicillin Resistant Staphylococcus Aureus (MRSA)","status":"TERMINATED","sponsor":"B. Braun Medical SA","startDate":"2010-02","conditions":["MRSA - Methicillin Resistant Staphylococcus Aureus Infection","MRSA Colonization"],"enrollment":99,"completionDate":"2011-12"},{"nctId":"NCT01153828","phase":"","title":"EU PV for Retapamulin-Prescribing","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-11","conditions":["Impetigo"],"enrollment":1,"completionDate":"2012-08"},{"nctId":"NCT01153880","phase":"","title":"United States Pharmacovigilence Retapamulin-Prescribing","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12","conditions":["Skin Infections, Bacterial"],"enrollment":1,"completionDate":"2012-08"},{"nctId":"NCT01232231","phase":"NA","title":"Comprehensive Strategy to Decolonize Methicillin-resistant Staphylococcus Aureus (MRSA) in the Outpatient Setting","status":"COMPLETED","sponsor":"Joseph Kim","startDate":"2010-07","conditions":["Methicillin-resistant Staphylococcus Aureus"],"enrollment":15,"completionDate":"2012-11"},{"nctId":"NCT01611909","phase":"PHASE2,PHASE3","title":"Citriodiol® and Impetigo","status":"UNKNOWN","sponsor":"Royal North Shore Hospital","startDate":"2012-07","conditions":["Impetigo"],"enrollment":30,"completionDate":"2013-03"},{"nctId":"NCT00731783","phase":"NA","title":"Staphylococcus Aureus Decolonization Study","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2008-07","conditions":["Staphylococcal Skin Infections","Abscesses","Furunculosis","Staphylococcus Aureus","MRSA Infection"],"enrollment":183,"completionDate":"2010-12"},{"nctId":"NCT01152593","phase":"NA","title":"Effect of Intranasal Mupirocin on Rate of Staphylococcus Aureus Surgical Site Infection Following Cesarean Sections","status":"UNKNOWN","sponsor":"Hillel Yaffe Medical Center","startDate":"2010-07","conditions":["Surgical Wound Infection","Cesarean Section","Staphylococcus Aureus"],"enrollment":400,"completionDate":"2014-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Topical","formulation":"Cream, Ointment","formulations":[{"form":"CREAM","route":"TOPICAL","productName":"MUPIROCIN"},{"form":"CREAM","route":"TOPICAL","productName":"Mupirocin"},{"form":"CREAM","route":"TOPICAL","productName":"Pirnuo"},{"form":"CREAM","route":"TOPICAL","productName":"BACTROBAN"},{"form":"CREAM","route":"TOPICAL","productName":"Bactroban"},{"form":"CREAM","route":"TOPICAL","productName":"LEVOCETIRIZINE DIHYDROCHLORIDE 2% / MUPIROCIN 2% / TRIAMCINOLONE ACETONIDE 0.025%"},{"form":"OINTMENT","route":"TOPICAL","productName":"MUPIROCIN"},{"form":"OINTMENT","route":"TOPICAL","productName":"MUPIROCIN2%"},{"form":"OINTMENT","route":"TOPICAL","productName":"Mupirocin"},{"form":"OINTMENT","route":"TOPICAL","productName":"mupirocin"},{"form":"OINTMENT","route":"TOPICAL","productName":"BACTROBAN"},{"form":"OINTMENT","route":"TOPICAL","productName":"CENTANY"},{"form":"OINTMENT","route":"TOPICAL","productName":"Centany AT"},{"form":"OINTMENT","route":"TOPICAL","productName":"Mupirocin Calcium"},{"form":"OINTMENT","route":"TOPICAL","productName":"LIDOCAINE 2% / MUPIROCIN 2%"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147519","MMSL":"198973","NDDF":"002802","UNII":"D0GX863OA5","VUID":"4019345","CHEBI":"CHEBI:7025","VANDF":"4019345","INN_ID":"5276","RXNORM":"221128","UMLSCUI":"C0085259","chemblId":"CHEMBL3989715","ChEMBL_ID":"CHEMBL3989715","KEGG_DRUG":"D01076","DRUGBANK_ID":"DB00410","PDB_CHEM_ID":" MRC","PUBCHEM_CID":"446596","SNOMEDCT_US":"387397004","IUPHAR_LIGAND_ID":"10916","SECONDARY_CAS_RN":"115074-43-6","MESH_DESCRIPTOR_UI":"D016712"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1987-","companyName":"GSK","relationship":"Original Developer"}],"publicationCount":2357,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"D06AX09","allCodes":["D06AX09","R01AX06"]},"biosimilarFilings":[],"originalDeveloper":"Glaxosmithkline","recentPublications":[{"date":"2026 Mar 13","pmid":"41900409","title":"In Vitro Activity of Mupirocin Against Methicillin-Resistant Staphylococcus aureus (MRSA) in Two Periods of Time (2016 and 2021-2022) in a Large University Hospital in Germany.","journal":"Microorganisms"},{"date":"2026 Mar 14","pmid":"41892459","title":"Iron(III)-Tropolone Complex as a Topical Agent Against Drug-Resistant MRSA Skin Infections.","journal":"Antibiotics (Basel, Switzerland)"},{"date":"2026 Mar 18","pmid":"41862082","title":"Mupirocin-based Nasal Decolonization to Prevent Staphylococcus aureus Surgical Site Infections: A Meta-Analysis of Randomized Control Trials.","journal":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases"},{"date":"2026 Feb","pmid":"41839109","title":"Impetigo: Rapid Evidence Review.","journal":"American family physician"},{"date":"2026","pmid":"41834997","title":"Synergistic activity of mupirocin in combination with protocatechuic acid ethyl ester against mupirocin-resistant MRSA.","journal":"Frontiers in cellular and infection microbiology"}],"companionDiagnostics":[],"genericManufacturers":6,"_genericFilersChecked":true,"genericManufacturerList":["Encube","Fougera Pharms","Glenmark Pharms","Padagis Israel","Sun Pharma Canada","Teva"],"status":"approved","companyName":"Glaxosmithkline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"1987","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1987-12-31T00:00:00.000Z","mah":"GLAXOSMITHKLINE","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:46:24.913035+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}